Literature DB >> 19461157

Cytoplasmic localization of Jab1 and p27 Kip1 might be associated with invasiveness of papillary thyroid carcinoma.

Jihyun Ahn1, Soon Auck Hong, Seung-Eun Lee, Jaetaek Kim, Yeon Sahng Oh, Sung Jun Park, Yun Jae Chung.   

Abstract

p27(kip1) is a well known negative regulator of cell cycle progression. Jab1 directly binds to p27(kip1) and induces nuclear export and subsequent degradation. Recent studies have shown that overexpression of Jab1 and reduced expression of p27(kip1) are associated with advanced tumor stage and poor prognosis in several human cancers. Here, we evaluated 50 papillary thyroid carcinomas (PTC) and adjacent normal thyroid tissue samples by immunohistochemistry for Jab1 and p27(kip1) to elucidate expression levels and subcellular localization. Expression of Jab1 was markedly increased and that of p27(kip1) was reduced in the tumors compared with paired normal samples. Jab1 expression was inversely related to p27(kip1) expression. Jab1 was especially overexpressed within the invasive region compared to center of the tumors. Among clinicopathologic parameters, only tumor size was related with Jab1 (positively) and p27(kip1) expression (negatively) in the invasive region of the tumors. Both Jab1 and p27(kip1) were found predominantly in the cytoplasm of the tumor cells from the invasive regions compared to center of the tumors. The Ki-67 proliferative index was higher in the invasive region than in center of the tumors. A much stronger correlation with the Ki-67 index was noted when both Jab1 and p27(kip1) were simultaneously localized in the cytoplasm than when either Jab1 or p27(kip1) was localized in the cytoplasm alone. These data suggest that in addition to overexpression of Jab1 and reduced expression of p27(kip1), cytoplasmic localization of Jab1 and p27(kip1) are associated with increased cancer cell proliferation and might be related to the invasiveness of PTC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19461157     DOI: 10.1507/endocrj.k08e-372

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  13 in total

1.  Jun activation domain-binding protein 1 expression in oral squamous cell carcinomas inversely correlates with the cell cycle inhibitor p27.

Authors:  Ling Gao; Shuo Huang; Wenhao Ren; Lu Zhao; Jingwei Li; Keqian Zhi; Yincheng Zhang; Hong Qi; Chen Huang
Journal:  Med Oncol       Date:  2012-02-04       Impact factor: 3.064

2.  Role of p97/Valosin-containing protein (VCP) and Jab1/CSN5 in testicular ischaemia-reperfusion injury.

Authors:  Sevil Cayli; Seda Ocakli; Ufuk Senel; Nilnur Eyerci; Tuncay Delibasi
Journal:  J Mol Histol       Date:  2016-01-11       Impact factor: 2.611

3.  Suppression of Jab1 expression inhibits proliferation and promotes apoptosis of AMC-HN-8 cells.

Authors:  Pei-Hua Li; Lin Wang; Yao-Jie Pan; Miao-Miao Sang; Jun-Nian Zheng; Dong-Sheng Pei
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

4.  JAB1/CSN5: a new player in cell cycle control and cancer.

Authors:  Terry J Shackleford; Francois X Claret
Journal:  Cell Div       Date:  2010-10-18       Impact factor: 5.130

5.  Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma.

Authors:  Li Chen; Daiyue Yuan; Gui-lan Wang; You Wang; Yuan-Yuan Wu; Jianwei Zhu
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

6.  Physical interaction of Jab1 with human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival.

Authors:  Hyung-Mun Yun; Ja-Hyun Baik; Insug Kang; Changbae Jin; Hyewhon Rhim
Journal:  J Biol Chem       Date:  2010-01-21       Impact factor: 5.157

Review 7.  Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer.

Authors:  Yunbao Pan; Huiling Yang; Francois X Claret
Journal:  Cancer Biol Ther       Date:  2014-02-04       Impact factor: 4.742

Review 8.  Targeting Jab1/CSN5 in nasopharyngeal carcinoma.

Authors:  Yunbao Pan; Francois X Claret
Journal:  Cancer Lett       Date:  2012-08-04       Impact factor: 8.679

9.  Clinical relevance of SKP2 alterations in metastatic melanoma.

Authors:  Amy E Rose; Guimin Wang; Douglas Hanniford; Stefano Monni; Ting Tu; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Michele Pagano; Farbod Darvishian; Madhu Mazumdar; Eva Hernando; Iman Osman
Journal:  Pigment Cell Melanoma Res       Date:  2010-10-21       Impact factor: 4.693

10.  Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.